Based on the Bioventus Inc stock forecast from 3 analysts, the average analyst target price for Bioventus Inc is USD 13.20 over the next 12 months. Bioventus Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bioventus Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Bioventus Inc’s stock price was USD 10.68. Bioventus Inc’s stock price has changed by -4.22% over the past week, -8.80% over the past month and +104.21% over the last year.
No recent analyst target price found for Bioventus Inc
No recent average analyst rating found for Bioventus Inc
Company Overview Bioventus Inc
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina. Read Less
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgica...Read More
Frequently Asked Questions About Bioventus Inc (BVS) Stock
Based on ratings from 3 analysts Bioventus Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on BVS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BVS is USD 13.20 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on BVS's stock to indicate if its overvalued.
The last closing price of BVS's stock was USD 10.68.
The most recent market capitalization for BVS is USD 0.80B.
Based on targets from 3 analysts, the average taret price for BVS is projected at USD 13.20 over the next 12 months.
This means that BVS's stock price may go up by +23.60% over the next 12 months.
We can't find any ETFs which contains Bioventus Inc's stock.
As per our most recent records Bioventus Inc has 1,030 Employees.
Bioventus Inc's registered address is 4721 Emperor Boulevard, Durham, NC, United States, 27703.
You can get more information about it from Bioventus Inc's website at https://www.bioventus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bioventus Inc (BVS) Stock
Based on ratings from 3 analysts Bioventus Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on BVS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BVS is USD 13.20 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on BVS's stock to indicate if its overvalued.
The last closing price of BVS's stock was USD 10.68.
The most recent market capitalization for BVS is USD 0.80B.
Based on targets from 3 analysts, the average taret price for BVS is projected at USD 13.20 over the next 12 months.
This means that BVS's stock price may go up by +23.60% over the next 12 months.
We can't find any ETFs which contains Bioventus Inc's stock.
As per our most recent records Bioventus Inc has 1,030 Employees.
Bioventus Inc's registered address is 4721 Emperor Boulevard, Durham, NC, United States, 27703.
You can get more information about it from Bioventus Inc's website at https://www.bioventus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BVS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
